EN DE
STOCK COMPARISON

Macrogen vs MEDIPOST Co.: Fair Value & Quality

Both stocks run through our valuation models. Here is how Macrogen (038290) and MEDIPOST Co. (078160) compare, as of Aug 10, 2026.

As of Aug 10, 2026, Fair Value Calculator sees MEDIPOST Co. as the less overvalued of the two: Macrogen trades at KRW 12,320 versus a fair value of KRW 4,457 (-64%), while MEDIPOST Co. trades at KRW 9,850 versus KRW 3,628 (-63%).
Macrogen
038290.KQ · KRW · Health Care
-64%
upside to fair value
overvalued
PriceKRW 12,320
Fair ValueKRW 4,457
Quality48/100
MEDIPOST Co.
078160.KQ · KRW · Health Care
-63%
upside to fair value
overvalued
PriceKRW 9,850
Fair ValueKRW 3,628
Quality26/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

MacrogenMEDIPOST Co.
Valuation
1.9%Dividend yield—
Profitability
2%Net margin4%
3%Operating margin-26%
1%Return on assets-3%
Growth
25%Revenue growth (YoY)23%
12.1%Avg. growth/yr (3Y)4.7%
11.6%Avg. growth/yr (5Y)8.7%
Balance & size
0.10×Debt / equity0.03×
$85MMarket cap$240M
expensiveGrowth qualityexpensive

Macrogen leads: 5 to 2 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Macrogenof which business quality 48 · market factors 29 MEDIPOST Co.of which business quality 26 · market factors 18
ProfitabilityMargins and returns on capital today
26
4
Quality GrowthAre margins and returns improving?
85
32
CashflowEarnings quality: real cash, not paper profit
37
4
Fin. StrengthBalance sheet, leverage, solvency risk
36
59
InvestmentDisciplined investing over empire-building
56
72
Low VolatilityCalm price path (market factor)
69
39
MomentumPrice trend over the last 3–12 months (market factor)
12
5
52W MomentumDistance to the 52-week high (market factor)
13
15
Net IssuanceBuybacks instead of dilution
68
0

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Macrogen

Earnings-BasedKRW 2,694
MultiplesKRW 3,444
Asset-BasedKRW 10,514
Economic ProfitKRW 6,647
Growth EarningsKRW 3,736

13 of 14 models see the stock below the current price.

MEDIPOST Co.

Asset-BasedKRW 4,269

1 of 1 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Macrogen
Bear KRW 3,342Fair Value KRW 4,457Bull KRW 5,571
KRW 12,320 = current price (white tick)
MEDIPOST Co.
Bear KRW 2,708Fair Value KRW 3,628Bull KRW 5,415
KRW 9,850 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Macrogen · Health Care

Quality score48 · below median
Fair value upside-64% · bottom 25%

MEDIPOST Co. · Health Care

Quality score26 · bottom 25%
Fair value upside-63% · bottom 25%

Bottom line

As of Aug 10, 2026, Fair Value Calculator sees MEDIPOST Co. as the less overvalued of the two: Macrogen trades at KRW 12,320 versus a fair value of KRW 4,457 (-64%), while MEDIPOST Co. trades at KRW 9,850 versus KRW 3,628 (-63%).

Macrogen has the higher quality score (48/100).

See the full analysis →
Macrogen · MEDIPOST Co.

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Macrogen

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company

Related to MEDIPOST Co.

UnitedHealth Group vs AstraZenecaUnitedHealth Group vs Thermo Fisher ScientificUnitedHealth Group vs AmgenUnitedHealth Group vs Abbott Laboratories
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.